Juno Therapeutics, Inc., A Bristol-myers Squibb Company

This study compares a new CAR-T cell therapy called arlocabtagene autoleucel (arlo-cel) with standard treatments for adults whose multiple myeloma has returned or stopped responding to prior therapy. About 440 participants will receive either the CAR-T cells or standard regimens.…

This study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and destroy faulty B cells that drive lupus. It is for people with active systemic lupus erythematosus (SLE) or lupus nephritis who have not improved with steroids and…

This early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…

This early-stage study is testing a cell therapy called arlocabtagene autoleucel combined with other drugs (alnuctamab, mezigdomide, iberdomide, or elranatamab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has returned or stopped responding to at least four prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to…

This study tests a one-time infusion of specially engineered immune cells (lisocabtagene maraleucel) as the first treatment for primary central nervous system lymphoma in 65 adults who are not eligible for a stem cell transplant. The goal is to see if this therapy can control the…